Organization
Tokyo Medical and Dental University, Tokyo, Japan
3 abstracts
Abstract
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.Org: Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto University Hospital, Kyoto, Japan, Department of Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, The University of Tokyo Hospital, Tokyo, Japan, Tokyo Medical and Dental University, Bunkyo-Ku, Japan,
Abstract
BASELINE PARAMETERS IDENTIFIED IN EARLY, METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS WITH BETTER OUTCOMES WITH CERTOLIZUMAB PEGOL+METHOTREXATE COMPARED TO PLACEBO+METHOTREXATE: POST-HOC ANALYSES OF C-OPERA, A RANDOMIZED, CONTROLLED, PHASE 3 SOrg: Hokkaido University Graduate School of Medicine, Hokkaido, The University of Tokyo, Tokyo, Japan, Keio University School of Medicine, Tokyo Women's Medical University, Tokyo, Japan, Nagoya University, Nagoya,
Abstract
BETTER CLINICAL RESPONSES SEEN EARLY WITH THE LOADING DOSE OF CERTOLIZUMAB PEGOL ARE MAINTAINED UNTIL ONE YEAR Org: Keio University School of Medicine, University of Tokyo, Tokyo Women's Medical University, Tokyo, Japan, Nagoya University, Nagoya, University of Occupational and Environmental Health, Kitakyushu, Japan,